Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8893391 | 0.86 | KDM4E (0.50) | KDM4ENPC1SMN1; SMN2RAB9APKM | |
| SCHEMBL7981944 | 0.74 | PTGIR (0.46) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL11464553 | 0.73 | MEN1 (0.50) | KDM4ESMN1; SMN2GAAALDH1A1MAPT | |
| SCHEMBL7968757 | 0.73 | POLB (0.52) | KDM4ENPC1SMN1; SMN2RAB9APKM | |
| SCHEMBL22074391 | 0.73 | TRPM8 (0.52) | KDM4ENPC1SMN1; SMN2RAB9APKM | |
| SCHEMBL9069781 | 0.72 | LMNA (0.48) | KDM4ENPC1SMN1; SMN2GAACYP2C19 | |
| SCHEMBL7978941 | 0.71 | TP53 (0.51) | NPC1SMN1; SMN2RAB9AGAAALDH1A1 | |
| SCHEMBL7980229 | 0.71 | NPC1 (0.66) | KDM4ENPC1SMN1; SMN2RAB9AMITF | |
| SCHEMBL7981765 | 0.70 | PTGIR (0.49) | KDM4ESMN1; SMN2GAACYP1A2CYP3A4 | |
| SCHEMBL11874279 | 0.70 | KMT2A (0.50) | KDM4ENPC1RAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501846-B1 | TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS | ABBOTT LAB (US) | 2009-03-18 | — | — | EP | disclosed |
| US-6992069-B2 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2006-01-31 | — | — | US | disclosed |
| US-20040029818-A1 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029818-A1 | Tricyclic macrolide antibacterial compounds | RPN1, CASP1, MRPL21 | KDM4E 4677/4885NPC1 9/4885SMN1; SMN2 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.